+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasopharyngeal Cancer - Pipeline Review, H2 2020

  • ID: 5146859
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 854 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Akeso Inc
  • AVEO Pharmaceuticals Inc
  • Exelixis Inc
  • Lion TCR Pte Ltd
  • Ono Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews the key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 29, 20, 1, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 7 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Akeso Inc
  • AVEO Pharmaceuticals Inc
  • Exelixis Inc
  • Lion TCR Pte Ltd
  • Ono Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • MORE
Introduction
  • Nasopharyngeal Cancer - Overview
  • Nasopharyngeal Cancer - Therapeutics Development
Nasopharyngeal Cancer - Therapeutics Assessment

Nasopharyngeal Cancer - Companies Involved in Therapeutics Development

Nasopharyngeal Cancer - Drug Profiles

Nasopharyngeal Cancer - Dormant Projects
  • Nasopharyngeal Cancer - Discontinued Products
  • Nasopharyngeal Cancer - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Nasopharyngeal Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
  • Nasopharyngeal Cancer - Pipeline by Akeso Inc, H2 2020
  • Nasopharyngeal Cancer - Pipeline by Alphamab Oncology, H2 2020
  • Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H2 2020
  • Nasopharyngeal Cancer - Dormant Projects, H2 2020
  • Nasopharyngeal Cancer - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Nasopharyngeal Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Advenchen Laboratories LLC
  • Akeso Inc
  • Alphamab Oncology
  • Ambrx Inc
  • Apollomics Inc
  • Argenx SE
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AVEO Pharmaceuticals Inc
  • BeiGene Ltd
  • Biomics Biotechnologies Co Ltd
  • Bristol-Myers Squibb Co
  • Chengdu Wonho Biology Engineering Co Ltd
  • China Immunotech Co Ltd
  • Cullinan Oncology LLC
  • CytoMed Therapeutics Pte Ltd
  • Eli Lilly and Co
  • Eutilex Co Ltd
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Geneius Biotechnology Inc
  • Guangzhou Doublle Bioproduct Inc
  • Guangzhou Hanghua Bio Pharmaceutical Technology Co
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Huabo Biopharm Co Ltd
  • Immunomic Therapeutics Inc
  • Incyte Corp
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kuur Therapeutics Ltd
  • Lion TCR Pte Ltd
  • Merck & Co Inc
  • Merck KGaA
  • Molecular Partners AG
  • Nanjing Iaso Biotherapeutics Co Ltd
  • Neonc Technologies Inc
  • Novartis AG
  • Noxopharm Ltd
  • Ono Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Oxford Vacmedix UK Ltd
  • PNP Therapeutics Inc
  • Polaris Pharmaceuticals Inc
  • RAPT Therapeutics Inc
  • Shanghai GeneChem Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Miracogen Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Tessa Therapeutics Ltd
  • Tevogen Bio Inc
  • TOT Biopharm Co Ltd
  • Vectorite Biomedical Inc
  • Viracta Therapeutics Inc
  • Xencor Inc
  • Xiangxue Life Sciences
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll